Semax is a synthetic heptapeptide derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH), specifically the ACTH(4–7) sequence extended with a Pro-Gly-Pro tripeptide. Originally developed in Russian research institutions during the 1980s and 1990s, Semax has since attracted significant preclinical interest globally for its interactions with neurotrophic signaling pathways, particularly those involving brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). As researchers continue to investigate neuropeptide biology in 2026, Semax remains one of the most studied short synthetic peptides in the context of central nervous system (CNS) research models.
Preclinical investigations into Semax have explored its influence on neurotrophin expression, neuroprotective mechanisms, cognitive function models, and cerebrovascular biology. Its compact structure, relative metabolic stability compared to native ACTH fragments, and intranasal bioavailability in animal models have made it a frequently referenced compound in neuropeptide research literature. This guide provides a structured overview of Semax’s molecular biology, documented preclinical findings, and its role within the broader landscape of research peptides studied in laboratory settings.
Research-only notice: This content is provided for educational discussion and laboratory research purposes only. No medical claims are made or implied.
Semax - 5MG — Research-Grade Reference Material Semax - 5MG is supplied as a lyophilized powder for in-vitro laboratory research use only. SourcePeptides supplies this material strictly as a laboratory reference standard.…
View Research Data
Pfizer Hospira Bacteriostatic Water – 30 mL
$45.00$33.75 with 1st order
Ara-290 10MG
$45.00$33.75 with 1st order
Epithalon - 10MG
$50.00$37.50 with 1st order
GLP-2 (T) 45MG
$225.00$168.75 with 1st order
Frequently Asked Questions
What is Semax peptide?
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the ACTH(4–7) fragment with an added Pro-Gly-Pro C-terminal extension. It was developed as a research compound to study neuropeptide biology, neurotrophic signaling, and CNS mechanisms in preclinical models.
What receptor systems has Semax been studied in relation to?
Preclinical research has investigated Semax in relation to melanocortin receptors (particularly MC4R), as well as its downstream effects on BDNF, NGF, and VEGF signaling pathways. Studies have also examined its interactions with dopaminergic and serotonergic systems in rodent models.
What does preclinical research suggest about Semax and BDNF?
Several preclinical studies in rodent models have observed that Semax administration was associated with elevated BDNF mRNA expression in the hippocampus and other brain regions. Researchers have proposed this neurotrophic modulation as a potential mechanism underlying the cognitive and neuroprotective observations made in those models.
How does Semax differ structurally from native ACTH?
Native ACTH is a 39-amino acid polypeptide. Semax is based only on the ACTH(4–7) sequence (Met-Glu-His-Phe), to which a Pro-Gly-Pro tripeptide was synthetically appended to increase metabolic stability and prolong biological activity in preclinical settings. The resulting heptapeptide lacks the corticotropic hormonal activity associated with full ACTH.
How is Semax typically studied in laboratory research?
In preclinical models, Semax has been studied via intranasal, subcutaneous, and intraperitoneal administration routes in rodents. Researchers have examined its effects on gene expression, neurotrophic factor levels, cerebral blood flow models, and behavioral assays related to learning and memory. It is available as a lyophilized research peptide for in vitro and in vivo laboratory use.
What is the relationship between Semax and Selank in research?
Both Semax and Selank are synthetic neuropeptides studied for their CNS-related mechanisms. Semax is an ACTH-derived peptide with documented BDNF and NGF-modulating properties, while Selank is a tuftsin-derived peptide with investigated anxiolytic and immune-modulating properties in preclinical models. They are sometimes studied together as complementary research compounds targeting different aspects of neurobiological signaling.
Is Semax the same as N-Acetyl Semax?
No. N-Acetyl Semax (also called NA-Semax) is an acetylated derivative of the original Semax peptide. Research suggests acetylation may alter the compound’s potency, receptor binding characteristics, and metabolic stability. Both are distinct research compounds studied separately in preclinical neuroscience literature.
Molecular Architecture of Semax
Semax carries the amino acid sequence Met-Glu-His-Phe-Pro-Gly-Pro, giving it a molecular weight of approximately 887 Da. The core ACTH(4–7) tetrapeptide (Met-Glu-His-Phe) retains partial melanocortin receptor affinity without the hormonal activity associated with the full ACTH molecule. The synthetic addition of the Pro-Gly-Pro tripeptide at the C-terminus was a deliberate design choice by Soviet-era researchers to improve resistance to enzymatic degradation by proline-specific endopeptidases — a common limitation of short neuropeptides in biological environments.
Semax - 5MG — Research-Grade Reference Material Semax - 5MG is supplied as a lyophilized powder for in-vitro laboratory research use only. SourcePeptides supplies this material strictly as a laboratory reference standard.…
View Research Data
Pfizer Hospira Bacteriostatic Water – 30 mL
$45.00$33.75 with 1st order
Ara-290 10MG
$45.00$33.75 with 1st order
Epithalon - 10MG
$50.00$37.50 with 1st order
GLP-2 (T) 45MG
$225.00$168.75 with 1st order
The Pro-Gly-Pro extension is itself a biologically interesting sequence. It has structural similarities to collagen-derived tripeptides and has been independently investigated for neuromodulatory properties, though in the context of Semax it is primarily studied as a stabilizing tail that extends the peptide’s half-life in CNS tissue. This engineering approach — grafting a stability-conferring sequence onto a pharmacologically active core — represents a strategy that appears across several generations of synthetic research neuropeptides.
Melanocortin Receptor Interactions
Melanocortin receptors (MCRs) are a family of G protein-coupled receptors (GPCRs) through which ACTH and related peptides exert their biological effects. The ACTH(4–7) core of Semax has been studied for its affinity at MC3R and MC4R subtypes, both of which are expressed throughout the CNS. MC4R in particular has attracted research interest due to its documented roles in energy regulation, cognitive signaling, and neuroprotection in preclinical models. Research into melanocortin biology via PT-141 research illustrates how diverse the downstream consequences of MCR engagement can be across different peptide scaffolds.
Neurotrophic Signaling: BDNF and NGF Pathways
One of the most consistently reported preclinical findings associated with Semax involves its apparent capacity to upregulate the expression of neurotrophic factors, particularly BDNF and NGF. Brain-derived neurotrophic factor is a member of the neurotrophin family that supports neuronal survival, synaptic plasticity, and hippocampal neurogenesis. In rodent studies, BDNF levels in the hippocampus and cortex have been observed to increase following Semax administration, an effect that researchers have linked to downstream activation of TrkB receptor signaling and subsequent CREB-mediated gene transcription.
A landmark series of studies published by Russian research groups in the early 2000s used quantitative PCR and immunohistochemistry to map BDNF mRNA changes across rat brain regions following intranasal Semax administration. These studies reported significant upregulation in hippocampal CA1, CA3, and dentate gyrus subfields — regions of particular importance in spatial memory and learning circuit models. NGF expression changes were also documented in the basal forebrain, a region densely populated with cholinergic neurons whose function is closely linked to attention and memory processing in animal models.
VEGF and Cerebrovascular Research Models
Beyond classic neurotrophins, preclinical Semax research has investigated its effects on vascular endothelial growth factor (VEGF) in the context of cerebral ischemia models. Studies in rodent stroke models have examined whether Semax-associated VEGF upregulation correlates with angiogenic responses and neuronal survival in the peri-infarct zone. Researchers have used middle cerebral artery occlusion (MCAO) models as a standard platform for these investigations, observing changes in infarct volume, VEGF transcript levels, and behavioral outcomes on sensorimotor tasks in treated versus control animals.
Preclinical Cognitive Biology Studies
A substantial body of preclinical literature has used standard rodent behavioral paradigms to investigate Semax’s effects on learning and memory-related processes. The Morris water maze, radial arm maze, and novel object recognition tasks have all been employed across multiple independent research groups. Collectively, these studies suggest that rodents administered Semax demonstrate altered performance on spatial and recognition memory tasks compared to vehicle-treated controls, though the mechanistic interpretation of these behavioral differences remains an active area of investigation.
Researchers studying cognitive neuropeptide biology often draw comparisons between Semax and other CNS-active research compounds. Noopept (GVS-111) research similarly documents preclinical evidence for BDNF pathway engagement, and the overlapping neurotrophic mechanisms between these distinct compound classes have been a focus of comparative neuropeptide research. Likewise, Dihexa peptide research has characterized HGF/c-Met signaling as another distinct route by which synthetic peptides may influence synaptic density and cognitive biology in animal models.
Attention and Arousal Models
In addition to memory paradigms, Semax has been examined in models related to attentional processing and arousal. Studies utilizing electroencephalographic (EEG) recordings in rodents have reported changes in cortical activity patterns consistent with increased alertness and focused attention states following peptide administration. Dopaminergic and serotonergic neurotransmission have been proposed as modulatory substrates for these effects, with some studies measuring monoamine metabolite levels in prefrontal cortical tissue as a proxy for neurotransmitter turnover.
Neuroprotective Biology in Preclinical Models
Semax has been investigated across several preclinical models of neurological insult. Beyond ischemia models, researchers have studied it in excitotoxicity paradigms (using glutamate or NMDA challenge), oxidative stress assays, and models of chronic neurodegenerative pathology. In excitotoxicity models, Semax-treated neuronal cell cultures and brain slice preparations have shown altered patterns of cell death markers — including reduced caspase-3 activation and changes in Bcl-2/Bax ratio — compared to untreated controls in several published in vitro studies.
The proposed neuroprotective mechanisms are multifactorial according to the literature. BDNF-mediated activation of the PI3K/Akt survival pathway, reduction in reactive oxygen species (ROS) production, and modulation of inflammatory cytokine profiles (particularly IL-6 and TNF-α) in glial cell preparations have all been reported as correlates of Semax exposure in various preclinical systems. Researchers studying MOTS-C peptide and mitochondrial biology have noted parallel themes around oxidative stress regulation in metabolically challenged neural tissue, highlighting how converging mechanistic pathways are studied across structurally distinct research peptides.
Optic Nerve and Retinal Research
An intriguing subset of Semax preclinical research has focused on the visual system. Given the high density of BDNF-responsive neurons in the retina and optic nerve, several Russian and Ukrainian research groups have investigated Semax in rodent and rabbit models of optic nerve transection and retinal ischemia. Histomorphometric analyses in these studies have documented differences in retinal ganglion cell survival and optic nerve fiber density between Semax-treated and control animals, framing the compound as a potentially informative tool for studying neurotrophic support mechanisms in ocular tissue.
Intranasal Delivery and CNS Bioavailability in Animal Models
One of the more distinctive research characteristics of Semax is its documented intranasal-to-CNS bioavailability in rodent models. Studies using radiolabeled Semax analogs have traced peptide distribution following intranasal administration, demonstrating uptake into olfactory bulb tissue and subsequent distribution to deeper brain structures including the hippocampus and hypothalamus. This pathway — exploiting olfactory nerve projections and the cribriform plate as a route bypassing the blood-brain barrier — has been of considerable interest to researchers studying CNS peptide delivery mechanisms.
This intranasal delivery research has parallels with work on other neuropeptides. Selank and Semax nasal spray research has explored how the delivery format affects tissue distribution and biological response profiles in animal models, an important methodological consideration when designing preclinical experiments with CNS-targeting peptides.
Semax 10MG Nasal Spray for research →
Semax 5MG lyophilized for laboratory use →
Semax in the Context of Neuropeptide Research Stacks
Research interest in Semax has expanded beyond single-compound studies to include investigation of its interactions with complementary neuropeptides. Selank — a tuftsin-derived heptapeptide with documented GABAergic and immune-modulatory properties in preclinical models — is the most commonly co-studied compound alongside Semax. The rationale is mechanistic complementarity: Semax research focuses on excitatory neurotrophic and dopaminergic biology, while Selank research explores anxiolytic and immunomodulatory pathways. Combined preclinical models have examined whether these mechanisms operate additively or synergistically in specific assay contexts.
Selank & Semax Stack Nasal Spray for research →
Selank & Semax 20MG combined for laboratory research →
Researchers interested in broader CNS peptide biology may also find value in reviewing nootropic peptide candidates like Dihexa and Pinealon, each of which operates through distinct receptor systems and transcriptional mechanisms, providing useful comparative frameworks when interpreting Semax data.
Where These Fit in Your Research Library
Researchers building a CNS-focused peptide library will find Semax a well-characterized reference compound with an extensive preclinical literature base. Related research compounds from the SourcePeptides catalog include:
- Selank 10MG Nasal Spray — for comparative GABAergic and anxiolytic pathway research
- Dihexa 10MG — for HGF/c-Met synaptic biology research models
- Pinealon 10MG — for epigenetic neuropeptide regulation studies
Explore the complete SourcePeptides research catalog for additional CNS, metabolic, and regenerative peptide compounds: Full Research Peptide Catalog →
Final Takeaway: Semax as a Neuropeptide Research Tool in 2026
Semax occupies a well-established position in preclinical neuropeptide research. Its ACTH-derived architecture, documented interactions with melanocortin receptors, and robust preclinical evidence for BDNF and NGF pathway modulation make it a compound of continued scientific relevance. The breadth of research — spanning cerebral ischemia models, cognitive behavioral paradigms, optic nerve biology, and neurotrophin gene expression studies — reflects the versatility of Semax as a tool for investigating fundamental questions in CNS biology.
For researchers studying neurotrophic signaling cascades, neuroprotective mechanisms, or the intersection of ACTH-derived peptide biology and cognitive function, Semax represents a structurally compact and well-validated research compound with a deep supporting literature. As 2026 research priorities continue to prioritize CNS peptide bioavailability and neurotrophic pathway modulation, Semax remains a foundational reference point in this evolving field.
Sources & Further Reading
- Dolotov OV et al. — “Semax, an analogue of ACTH(4–10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus” — Brain Research (2003)
- Agapova TY et al. — “Effects of ACTH(4–7)PGP (Semax) on the expression of BDNF and NGF mRNAs in rat cholinergic neurons” — Doklady Biological Sciences (2006)
- Mironova VI et al. — “Semax affects the expression of genes involved in neurotrophin signaling and neuroprotection” — Journal of Neurochemistry (2008)
- PubMed Search — Semax neuropeptide BDNF preclinical research literature
- PubMed Search — Semax ACTH melanocortin receptor biology studies
